Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

IO Biotech, Inc. (IOBT)

Compare
1.0050
-0.0650
(-6.07%)
At close: April 3 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IOBT

Recent News: IOBT

View More
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire 9 days ago
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025
GlobeNewswire 16 days ago
IO Biotech Reports 2024 Business Highlights

IO Biotech Reports 2024 Business Highlights
GlobeNewswire 30 days ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
GlobeNewswire last month
IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech to Present at the 45th Annual Cowen Health Care Conference
GlobeNewswire last month
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
GlobeNewswire last month
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy

IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
Clinical Trials Arena 2 months ago
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
GlobeNewswire 2 months ago
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
GlobeNewswire 3 months ago
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire 4 months ago
IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire 4 months ago
View More

Related Tickers

IRD Opus Genetics, Inc.
0.9799
+5.07%
 
GRCE Grace Therapeutics, Inc.
2.2000
-4.76%
 
MIST Milestone Pharmaceuticals Inc.
0.7500
-6.61%
 
LPCN Lipocine Inc.
3.1000
-2.21%
 
APLT Applied Therapeutics, Inc.
0.4101
-7.01%
 
CNTB Connect Biopharma Holdings Limited
0.5900
-6.44%
 
ATRA Atara Biotherapeutics, Inc.
5.92
-3.43%
 
FDMT 4D Molecular Therapeutics, Inc.
2.8850
-12.04%
 
MURA Mural Oncology plc
1.2300
-6.82%
 
LYRA Lyra Therapeutics, Inc.
0.1111
-4.72%